{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:45Z","timestamp":1786982205276,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Gansu Province Outstanding Postgraduate Students \u201cStar of Innovation\u201d Project","award":["2023CXZX-144"],"award-info":[{"award-number":["2023CXZX-144"]}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["22JR5RA494"],"award-info":[{"award-number":["22JR5RA494"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["22JR5RA501"],"award-info":[{"award-number":["22JR5RA501"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871919"],"award-info":[{"award-number":["81871919"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02645-0","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T23:42:02Z","timestamp":1742427722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["ADAM9 mediates Cisplatin resistance in gastric cancer cells through DNA damage response pathway"],"prefix":"10.1007","volume":"42","author":[{"given":"Xiao-yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-yuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-ming","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cun-pu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-na","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-ning","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"issue":"10251","key":"2645_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. Lancet. 2020;396(10251):635\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(20)31288-5.","journal-title":"Lancet"},{"issue":"16","key":"2645_CR2","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3748\/wjg.v29.i16.2452","volume":"29","author":"WJ Yang","year":"2023","unstructured":"Yang WJ, Zhao HP, Yu Y, et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol. 2023;29(16):2452\u201368. https:\/\/doi.org\/10.3748\/wjg.v29.i16.2452.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"2645_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00280-023-04572-1","volume":"92","author":"CQ Liu","year":"2023","unstructured":"Liu CQ, Li S, Tang YL. Mechanism of cisplatin resistance in gastric cancer and associated microRNAs. Cancer Chemoth Pharm. 2023;92(5):329\u201340. https:\/\/doi.org\/10.1007\/s00280-023-04572-1.","journal-title":"Cancer Chemoth Pharm"},{"key":"2645_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.semcancer.2020.08.013","volume":"77","author":"M McMullen","year":"2021","unstructured":"McMullen M, Madariaga A, Lheureux S. New approaches for targeting platinum-resistant ovarian cancer. Semin Cancer Biol. 2021;77:167\u201381. https:\/\/doi.org\/10.1016\/j.semcancer.2020.08.013.","journal-title":"Semin Cancer Biol"},{"key":"2645_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364\u201378. https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.025.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"2645_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrc2342","volume":"8","author":"T Helleday","year":"2008","unstructured":"Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193\u2013204. https:\/\/doi.org\/10.1038\/nrc2342.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2645_CR7","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1158\/2159-8290.CD-22-1220","volume":"13","author":"V Klapp","year":"2023","unstructured":"Klapp V, Alvarez-Abril B, Leuzzi G, et al. The DNA damage response and inflammation in cancer. Cancer Discov. 2023;13(7):1521\u201345. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1220.","journal-title":"Cancer Discov"},{"issue":"5","key":"2645_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.semcancer.2006.07.004","volume":"16","author":"S Gasser","year":"2006","unstructured":"Gasser S, Raulet D. The DNA damage response, immunity and cancer. Semin Cancer Biol. 2006;16(5):344\u20137. https:\/\/doi.org\/10.1016\/j.semcancer.2006.07.004.","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"2645_CR9","doi-asserted-by":"publisher","first-page":"103662","DOI":"10.1016\/j.drudis.2023.103662","volume":"28","author":"B Priya","year":"2023","unstructured":"Priya B, Ravi S, Kirubakaran S. Targeting ATM and ATR for cancer therapeutics: inhibitors in clinic. Drug Discov Today. 2023;28(8):103662.","journal-title":"Drug Discov Today"},{"issue":"3","key":"2645_CR10","first-page":"305","volume":"22","author":"LJ Kuo","year":"2008","unstructured":"Kuo LJ, Yang LX. Gamma-H2AX\u2014a novel biomarker for DNA double-strand breaks. In Vivo. 2008;22(3):305\u20139.","journal-title":"In Vivo"},{"key":"2645_CR11","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2020.3","volume":"22","author":"HL Smith","year":"2020","unstructured":"Smith HL, Southgate H, Tweddle DA, Curtin NJ. DNA damage checkpoint kinases in cancer. Expert Rev Mol Med. 2020;22: e2. https:\/\/doi.org\/10.1017\/erm.2020.3.","journal-title":"Expert Rev Mol Med"},{"key":"2645_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","volume":"108","author":"J Smith","year":"2010","unstructured":"Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010;108:73\u2013112. https:\/\/doi.org\/10.1016\/B978-0-12-380888-2.00003-0.","journal-title":"Adv Cancer Res"},{"issue":"4","key":"2645_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2015.1012976","volume":"2","author":"G Manic","year":"2015","unstructured":"Manic G, Obrist F, Sistigu A, Vitale I. Trial watch: targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy. Mol Cell Oncol. 2015;2(4): e1012976. https:\/\/doi.org\/10.1080\/23723556.2015.1012976.","journal-title":"Mol Cell Oncol"},{"issue":"4","key":"2645_CR14","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1083\/jcb.132.4.717","volume":"132","author":"G Weskamp","year":"1996","unstructured":"Weskamp G, Kratzschmar J, Reid MS, Blobel CP. MDC9, a widely expressed cellular disintegrin containing cytoplasmic SH3 ligand domains. J Cell Biol. 1996;132(4):717\u201326. https:\/\/doi.org\/10.1083\/jcb.132.4.717.","journal-title":"J Cell Biol"},{"issue":"13","key":"2645_CR15","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1007\/s00018-018-2796-x","volume":"75","author":"VO Oria","year":"2018","unstructured":"Oria VO, Lopatta P, Schilling O. The pleiotropic roles of ADAM9 in the biology of solid tumors. Cell Mol Life Sci. 2018;75(13):2291\u2013301. https:\/\/doi.org\/10.1007\/s00018-018-2796-x.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2645_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/19336918.2020.1817251","volume":"14","author":"MA Haoyuan","year":"2020","unstructured":"Haoyuan MA, Yanshu LI. Structure, regulatory factors and cancer-related physiological effects of ADAM9. Cell Adh Migr. 2020;14(1):165\u201381. https:\/\/doi.org\/10.1080\/19336918.2020.1817251.","journal-title":"Cell Adh Migr"},{"key":"2645_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207790","author":"CW Chou","year":"2020","unstructured":"Chou CW, Huang YK, Kuo TT, et al. An overview of ADAM9: structure, activation, and regulation in human diseases. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21207790.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2645_CR18","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.7150\/thno.53176","volume":"11","author":"WC Cheng","year":"2021","unstructured":"Cheng WC, Chang CY, Lo CC, et al. Identification of theranostic factors for patients developing metastasis after surgery for early-stage lung adenocarcinoma. Theranostics. 2021;11(8):3661\u201375. https:\/\/doi.org\/10.7150\/thno.53176.","journal-title":"Theranostics"},{"issue":"3","key":"2645_CR19","doi-asserted-by":"publisher","first-page":"760","DOI":"10.7150\/ijbs.77495","volume":"19","author":"AC Chang","year":"2023","unstructured":"Chang AC, Lin LW, Chen YC, et al. The ADAM9\/WISP-1 axis cooperates with osteoblasts to stimulate primary prostate tumor growth and metastasis. Int J Biol Sci. 2023;19(3):760\u201371. https:\/\/doi.org\/10.7150\/ijbs.77495.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"2645_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/1878-0261.12958","volume":"16","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Ma WJ, Hu WW, et al. Ubiquitin-specific peptidase 39 promotes human glioma cells migration and invasion by facilitating ADAM9 mRNA maturation. Mol Oncol. 2022;16(2):388\u2013404. https:\/\/doi.org\/10.1002\/1878-0261.12958.","journal-title":"Mol Oncol"},{"issue":"23","key":"2645_CR21","first-page":"10324","volume":"23","author":"WJ Qin","year":"2019","unstructured":"Qin WJ, Lv LH, Zhang M, et al. MiR-126 inhibits cell migration and invasion by targeting ADAM9 in oral squamous cell carcinoma. Eur Rev Med Pharmacol Sci. 2019;23(23):10324\u201331.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2645_CR22","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.2147\/Cmar.S231042","volume":"12","author":"G Yin","year":"2020","unstructured":"Yin G, Tian PR, BuHe A, et al. LncRNA LINC00689 promotes the progression of gastric cancer through upregulation of ADAM9 by sponging miR-526b-3p. Cancer Manag Res. 2020;12:4227\u201339. https:\/\/doi.org\/10.2147\/Cmar.S231042.","journal-title":"Cancer Manag Res"},{"issue":"14","key":"2645_CR23","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.7150\/ijbs.65488","volume":"17","author":"YS Lin","year":"2021","unstructured":"Lin YS, Kuo TT, Lo CC, et al. ADAM9 functions as a transcriptional regulator to drive angiogenesis in esophageal squamous cell carcinoma. Int J Biol Sci. 2021;17(14):3898\u2013910. https:\/\/doi.org\/10.7150\/ijbs.65488.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"2645_CR24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/pros.21237","volume":"71","author":"S Josson","year":"2011","unstructured":"Josson S, Anderson CS, Sung SY, et al. Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy. Prostate. 2011;71(3):232\u201340. https:\/\/doi.org\/10.1002\/pros.21237.","journal-title":"Prostate"},{"issue":"1","key":"2645_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3892\/or.2016.5259","volume":"37","author":"Q Fu","year":"2017","unstructured":"Fu Q, Cheng J, Zhang JD, et al. miR-20b reduces 5-FU resistance by suppressing the ADAM9\/EGFR signaling pathway in colon cancer. Oncol Rep. 2017;37(1):123\u201330. https:\/\/doi.org\/10.3892\/or.2016.5259.","journal-title":"Oncol Rep"},{"key":"2645_CR26","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.2147\/Ott.S281238","volume":"14","author":"HF Gao","year":"2021","unstructured":"Gao HF, Xu JJ, Qiao F, Xue LJ. Depletion of hsa_circ_0000144 suppresses oxaliplatin resistance of gastric cancer cells by regulating miR-502-5p\/ADAM9 axis. Onco Targets Ther. 2021;14:2773\u201387. https:\/\/doi.org\/10.2147\/Ott.S281238.","journal-title":"Onco Targets Ther"},{"issue":"3","key":"2645_CR27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s43018-023-00720-x","volume":"5","author":"YK Huang","year":"2024","unstructured":"Huang YK, Cheng WC, Kuo TT, et al. Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy. Nat Cancer. 2024;5(3):400\u201319. https:\/\/doi.org\/10.1038\/s43018-023-00720-x.","journal-title":"Nat Cancer"},{"issue":"4","key":"2645_CR28","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.62347\/LODV2387","volume":"14","author":"JP Liu","year":"2024","unstructured":"Liu JP, Shen KY, Cheng WC, et al. ADAM9 drives the immunosuppressive microenvironment by cholesterol biosynthesis-mediated activation of IL6-STAT3 signaling for lung tumor progression. Am J Cancer Res. 2024;14(4):1850\u201365.","journal-title":"Am J Cancer Res"},{"key":"2645_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030745","author":"S Oh","year":"2020","unstructured":"Oh S, Park Y, Lee HJ, et al. A disintegrin and metalloproteinase 9 (ADAM9) in advanced hepatocellular carcinoma and their role as a biomarker during hepatocellular carcinoma immunotherapy. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12030745.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2645_CR30","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3892\/or.2017.5460","volume":"37","author":"JQ Wang","year":"2017","unstructured":"Wang JQ, Zhou YY, Fei XC, et al. ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126. Oncol Rep. 2017;37(4):2033\u201340. https:\/\/doi.org\/10.3892\/or.2017.5460.","journal-title":"Oncol Rep"},{"issue":"1","key":"2645_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13046-020-01682-z","volume":"39","author":"C Yang","year":"2020","unstructured":"Yang C, Zhang J, Ma Y, et al. Histone methyltransferase and drug resistance in cancers. J Exp Clin Cancer Res. 2020;39(1):173. https:\/\/doi.org\/10.1186\/s13046-020-01682-z.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"2645_CR32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","volume":"22","author":"H Jin","year":"2023","unstructured":"Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov. 2023;22(3):213\u201334. https:\/\/doi.org\/10.1038\/s41573-022-00615-z.","journal-title":"Nat Rev Drug Discov"},{"key":"2645_CR33","doi-asserted-by":"publisher","first-page":"6622342","DOI":"10.1155\/2021\/6622342","volume":"2021","author":"B Liu","year":"2021","unstructured":"Liu B, Wang R, Liu H. mir-126-5p promotes cisplatin sensitivity of non-small-cell lung cancer by inhibiting ADAM9. Biomed Res Int. 2021;2021:6622342. https:\/\/doi.org\/10.1155\/2021\/6622342.","journal-title":"Biomed Res Int"},{"issue":"2","key":"2645_CR34","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/cas.13469","volume":"109","author":"M Ueno","year":"2018","unstructured":"Ueno M, Shiomi T, Mochizuki S, et al. ADAM9 is over-expressed in human ovarian clear cell carcinomas and suppresses cisplatin-induced cell death. Cancer Sci. 2018;109(2):471\u201382. https:\/\/doi.org\/10.1111\/cas.13469.","journal-title":"Cancer Sci"},{"issue":"26","key":"2645_CR35","doi-asserted-by":"publisher","first-page":"eadf2860","DOI":"10.1126\/sciadv.adf2860","volume":"9","author":"E Oropeza","year":"2023","unstructured":"Oropeza E, Seker S, Carrel S, et al. Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness. Sci Adv. 2023;9(26):eadf2860. https:\/\/doi.org\/10.1126\/sciadv.adf2860.","journal-title":"Sci Adv"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02645-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02645-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02645-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T20:23:53Z","timestamp":1743366233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02645-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["2645"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02645-0","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"3 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"122"}}